HER2-Positive Breast Cancer: A Guide Through An Evolving Treatment Landscape

Learn the latest practice-changing clinical data and expert recommendations to optimize clinical outcomes for your patients with HER2-positive breast cancer.


- Evolving Concepts in HER2 Evaluation
- Case Discussion: Neoadjuvant, Adjuvant, and Extended-Adjuvant Therapy Options for Early HER2-Positive Breast Cancer
- Case Discussion: Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
- Management of CNS Metastases
- Audience Question and Answer Session


Date / Time
Event Details


Jame Abraham, MD, FACP

Chairman, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio

Hope Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with HER2-positive breast cancer.

Target Audience 
This program is intended for oncologists, physician assistants, nurses, pharmacists, and other clinicians involved in the management of patients with HER2-positive breast cancer.

Learning Objectives

  • Plan optimal adjuvant and/or extended adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
  • Apply the latest clinical evidence on HER2-targeted agents to treat patients with HER2-low–expressing tumors
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and CNS metastases
  • Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hour (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-017-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.